Armata Pharmaceuticals (ARMP) Expected to Announce Earnings on Wednesday

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) will likely be announcing its Q3 2026 resultson Wednesday, November 11th. Analysts expect Armata Pharmaceuticals to post earnings of ($0.57) per share and revenue of $0.45 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.17. Armata Pharmaceuticals had a negative net margin of 3,467.04% and a negative return on equity of 12.24%. The business had revenue of $2.51 million during the quarter, compared to analysts’ expectations of $0.40 million. On average, analysts expect Armata Pharmaceuticals to post $0.50 EPS for the current fiscal year and ($2.04) EPS for the next fiscal year.

Armata Pharmaceuticals Stock Performance

Shares of Armata Pharmaceuticals stock opened at $3.09 on Wednesday. Armata Pharmaceuticals has a 1 year low of $2.74 and a 1 year high of $14.98. The business has a 50 day moving average price of $4.10 and a 200 day moving average price of $6.95.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of Armata Pharmaceuticals in a report on Tuesday, September 22nd. Two analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $15.00.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing targeted bacteriophage therapies for drug-resistant bacterial infections. Bacteriophages, or phages, are viruses that selectively infect and destroy specific bacteria, offering a potential alternative or complement to conventional antibiotics.

The company’s pipeline has included inhaled and intravenously administered phage candidates designed to treat serious infections caused by pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus.